UCSF-led Study Shows Oncotype DX and MRI May Provide Independent Information in Favorable Risk Prostate Cancer

Loading...
Loading...
Genomic Health, Inc.
GHDX
today announced results from a study led by the University of California, San Francisco (UCSF) showing a broad distribution of Oncotype DX® Genomic Prostate Score (GPS) results among prostate MRI findings, suggesting that these two technologies may provide non-overlapping clinical information in men with localized prostate cancer. "For the first time, we looked at the association between information provided by a genomic assay and a prostate MRI to better understand the value these two technologies bring to clinical practice," said Michael Leapman, M.D., lead investigator from UCSF. "These new data show that, in some patients, further risk stratification may be possible, and tools such as GPS may add important biological information to more precisely assess the aggressiveness of a patient's cancer." In this study, researchers conducted a retrospective evaluation of the statistical association between the Oncotype DX GPS results and contributing gene groups with baseline endorectal MRI in 100 patients with clinically localized prostate cancer. The results showed a large variation of GPS results across MRI findings, demonstrating that Oncotype DX and MRI offer non-overlapping clinical insights in patients with early-stage prostate cancer. "The ability to predict whether a man is likely to harbor an aggressive form of the disease helps guide appropriate treatment discussion with the patient," said Peter Carroll, M.D., M.P.H., professor and chair, Department of Urology, UCSF. "With recent advances in imaging technology and the availability of a test such as Oncotype DX, physicians now have the ability to use both anatomical and genomic information to identify patients for active surveillance, as well as those who may need to consider an immediate treatment." These new results follow the recent publication in Urology Practice of the first decision impact study of the Oncotype DX prostate cancer test that showed use of the test substantially increased the number of men who would be eligible for active surveillance while increasing physician confidence in their treatment recommendations. "We believe these results, as well as our recent clinical utility studies, underscore the value of Oncotype DX in providing important biologic information to improve risk assessment and treatment recommendations in patients with newly diagnosed prostate cancer," said Phil Febbo, M.D., chief medical officer, Genomic Health.
Loading...
Loading...
Posted In: NewsPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...